Clinical trial
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
NCT01253551 is registered in ClinicalTrials.gov with Tibotec BVBA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
- Lead sponsor
- Tibotec BVBA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- April 30, 2011
- Enrollment
- 21 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.